Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis

Systemic mastocytosis in a patient with Cowden syndrome

(2014) Srinivas K. Tantravahi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

(2014) Carlo Gambacorti-Passerini et al.   AMERICAN JOURNAL OF HEMATOLOGY

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

(2011) K. V. Gleixner et al.   BLOOD

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis

(2011) Celalettin Ustun et al.   LEUKEMIA RESEARCH

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

(2009) K.-H. Lim et al.   BLOOD

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V

(2008) Celalettin Ustun et al.   LEUKEMIA RESEARCH